Sovaldi, Harvoni Face First Safety Issue With Post-Marketing Cardiac Events
This article was originally published in The Pink Sheet Daily
Executive Summary
Gilead issues “Dear Healthcare Provider” letter outlining nine cases of bradycardia in patients who received amiodarone in combination with one of its HCV polymerase inhibitors; FDA has updated labeling for both drugs.